Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Keratitis Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Keratitis Overview | 8 | 1 |
| Pipeline Products for Keratitis Comparative Analysis | 9 | 1 |
| Keratitis Therapeutics under Development by Companies | 10 | 1 |
| Keratitis Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Keratitis Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Keratitis Products under Development by Companies | 15 | 1 |
| Keratitis Products under Investigation by Universities/Institutes | 16 | 1 |
| Keratitis Companies Involved in Therapeutics Development | 17 | 7 |
| Adamis Pharmaceuticals Corporation | 17 | 1 |
| Dompe Farmaceutici S.p.A. | 18 | 1 |
| NanoViricides, Inc. | 19 | 1 |
| ReceptoPharm, Inc. | 20 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 21 | 1 |
| SIFI S.p.A | 22 | 1 |
| The Medicines Company | 23 | 1 |
| Keratitis Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 27 |
| acyclovir sodium Drug Profile | 33 | 1 |
| B-2088 Drug Profile | 34 | 1 |
| C-31G Drug Profile | 35 | 2 |
| dipyridamole Drug Profile | 37 | 1 |
| Herpecide Drug Profile | 38 | 2 |
| IBN-1 Drug Profile | 40 | 1 |
| JDE-004 Drug Profile | 41 | 1 |
| PIM-45 Drug Profile | 42 | 1 |
| polihexanide Drug Profile | 43 | 1 |
| Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology Drug Profile | 44 | 2 |
| RGN-259 Drug Profile | 46 | 7 |
| RPI-MN Drug Profile | 53 | 2 |
| Small Molecule for Neurotrophic Keratitis Drug Profile | 55 | 1 |
| Small Molecules to Inhibit ATM for Herpes Keratitis Drug Profile | 56 | 1 |
| Synthetic Peptides for Bacterial Keratitis and Wounds Drug Profile | 57 | 1 |
| targocil Drug Profile | 58 | 1 |
| tigecycline Drug Profile | 59 | 1 |
| Keratitis Dormant Projects | 60 | 1 |
| Keratitis Discontinued Products | 61 | 1 |
| Keratitis Product Development Milestones | 62 | 7 |
| Featured News &Press Releases | 62 | 1 |
| Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China | 62 | 1 |
| May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease | 62 | 1 |
| Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday | 63 | 1 |
| Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency | 63 | 1 |
| Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials | 64 | 1 |
| Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial | 64 | 1 |
| Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259 | 65 | 1 |
| Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy | 65 | 1 |
| Sep 25, 2014: EuCornea: Dompe wins the Best Poster Award for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis | 66 | 1 |
| Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis | 67 | 1 |
| Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis | 68 | 1 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |